| dc.relation | 1. Shah H, Albanese E, Duggan C, et al. Research priorities to reduce the global burden
of dementia by 2025. Lancet Neurol 2016;15:1285–1294.
2. A neurology revival in Latin America. Lancet Neurol 2015;14:1143.
3. Alzheimer’s Disease International. World Alzheimer Report: Executive Summary.
London: Alzheimer’s Disease International;2009.
4. Manes F. The huge burden of dementia in Latin America. Lancet Neurol 2016;15:
29.
5. Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer’s disease and vascular dementia in
developing countries: prevalence, management, and risk factors. Lancet Neurol 2008;
7:812–826.
6. Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer’s disease: definition,
natural history, and diagnostic criteria. Alzheimers Dement 2016;12:292–323.
7. Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer’s prevention initiative: a plan
to accelerate the evaluation of presymptomatic treatments. J Alzheimer’s Dis 2011;26
(suppl 3):321–329.
8. Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease: the challenges
ahead. Nat Rev Neurol 2013;9:54–58.
9. Fox CJ, Lafortune L, Boustani M, Brayne C. The pros and cons of early diagnosis in
dementia. Br J Gen Pract 2013;63:e510–e512.
10. Brayne C, Fox CJ, Boustani M. Dementia screening in primary care: is it time? JAMA
2007;298:2409–2411.
11. Cece Y, Shifu X. Are the revised diagnostic criteria for Alzheimer’s disease useful in
low- and middle-income countries? Shanghai Arch Psychiatry 2015;27:119–123.
12. Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet 2016;388:
505–517.
13. Prince MJ, Wimo A, Guerchet MM, Ali GC, Wu YT, Prina M. World Alzheimer
Report 2015: The Global Impact of Dementia.London: Alzheimer’s Disease International;2015.
14. Alzheimer’s Disease International. World Alzheimer Report 2015. The Global impact
of dementia: an analysis of prevalence, incidence, cost & trends. World Alzheimer
Report 2015. Available at: alz.co.uk/research/world-report-2015. Accessed 2016.
15. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence
of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013;9:
63–75.
16. World Health Organization and Alzheimer’s Disease International. Dementia: A
Public Health Priority. Geneva: World Health Organization; 2012.
17. Jackson RL, Aparici G, Nakashima K, Strauss R, Howe N. Latin America’s Aging
Challenge: Demographics and Retirement Policy in Brazil, Chile, and Mexico.
Washington, DC: Center for Strategic and International Studies; 2009.
18. Sosa AL, Albanese E, Stephan BC, et al. Prevalence, distribution, and impact of mild
cognitive impairment in Latin America, China, and India: a 10/66 population-based
study. PLoS Med 2012;9:e1001170.
19. Llibre Rodriguez JJ, Ferri CP, Acosta D, et al. Prevalence of dementia in Latin
America, India, and China: a population-based cross-sectional survey. Lancet 2008;
372:464–474.
20. Prince M, Acosta D, Ferri CP, et al. Dementia incidence and mortality in middleincome countries, and associations with indicators of cognitive reserve: a 10/66
Dementia Research Group population-based cohort study. Lancet 2012;380:50–58.
21. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112–2117.
22. Mehta KM, Yeo GW. Systematic review of dementia prevalence and incidence in US
race/ethnic populations. Alzheimers Dement 2016;13:72–83.
23. Ramos-Cerqueira AT, Torres AR, Crepaldi AL, et al. Identification of dementia cases
in the community: a Brazilian experience. J Am Geriatr Soc 2005;53:1738–1742.
24. Maestre GE, Pino-Ramirez G, Molero AE, et al. The Maracaibo Aging Study: population and methodological issues. Neuroepidemiology 2002;21:194–201.
25. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in
Europe: a collaborative study of population-based cohorts: Neurologic Diseases in the
Elderly Research Group. Neurology 2000;54:S4–S9.
26. Sousa RM, Ferri CP, Acosta D, et al. Contribution of chronic diseases to disability in
elderly people in countries with low and middle incomes: a 10/66 Dementia Research
Group population-based survey. Lancet 2009;374:1821–1830.
27. Prince M, Comas-Herrera A, Knapp M, Guerchet M, Karagiannidou M. World Alzheimer Report 2016: Improving Healthcare for People Living With Dementia:
Coverage, Quality and Costs Now and in the Future. London: Alzheimer’s Disease
International; 2016.
28. Gleichgerrcht E, Flichtentrei D, Manes F. How much do physicians in Latin America
know about behavioral variant frontotemporal dementia? J Mol Neurosci 2011;45:
609–617.
29. Quiroz YT, Lopera F, Budson AE. Charting the path for early diagnosis and prevention of Alzheimer’s disease. Expert Rev Neurother 2011;11:1665–1667.
30. Gonzalez FJ, Gaona C, Quintero M, Chavez CA, Selga J, Maestre GE. Building
capacity for dementia care in Latin America and the Caribbean. Dement Neuropsychol 2014;8:310–316.
31. Ottersen OP, Dasgupta J, Blouin C, et al. The political origins of health inequity:
prospects for change. Lancet 2014;383:630–667.
32. Savedoff WD, de Ferranti D, Smith AL, Fan V. Political and economic aspects of the
transition to universal health coverage. Lancet 2012;380:924–932.
33. Tennstedt SL, Unverzagt FW. The ACTIVE study: study overview and major findings. J Aging Health 2013;25:3S–20S.
34. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet,
exercise, cognitive training, and vascular risk monitoring versus control to prevent
cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.
Lancet 2015;385:2255–2263.
35. Munoz-Neira C, Lopez OL, Riveros R, Nunez-Huasaf J, Flores P, Slachevsky A. The
technology–activities of daily living questionnaire: a version with a technology-related
subscale. Dement Geriatr Cogn Disord 2012;33:361–371.
36. Baez S, Ibanez A. Dementia in Latin America: an emergent silent tsunami. Front
Aging Neurosci 2016;8:253.
37. Reitz C, Mayeux R. Genetics of Alzheimer’s disease in Caribbean Hispanic and African
American populations. Biol Psychiatry 2014;75:534–541.
38. Sedeno L, Piguet O, Abrevaya S, et al. Tackling variability: a multicenter study to
provide a gold-standard network approach for frontotemporal dementia. Hum Brain
Mapp 2017;38:3804–3822.
39. Garcia AM, Abrevaya S, Kozono G, et al. The cerebellum and embodied semantics:
evidence from a case of genetic ataxia due to STUB1 mutations. J Med Genet 2017;54:
114–124.
40. Dottori M, Sedeno L, Martorell Caro M, et al. Towards affordable biomarkers of
frontotemporal dementia: a classification study via network’s information sharing. Sci
Rep 2017;7:3822.
41. Abrevaya S, Sedeno L, Fitipaldi S, et al. The road less traveled: alternative pathways for action-verb processing in Parkinson’s disease. J Alzheimer’s Dis 2017;55:
1429–1435.
42. Sedeño L, Couto B, Garc´ıa-Cordero I, et al. Brain network organization and social
executive performance in frontotemporal dementia. J Int Neuropsychol Soc 2016;22:
250–262.
43. Melloni M, Billeke P, Baez S, et al. Your perspective and my benefit: multiple lesion
models of self-other integration strategies during social bargaining. Brain 2016;139:
3022–3040.
44. Garc´ıa-Cordero I, Sedeño L, de la Fuente L, et al. Feeling, learning from, and being
aware of inner states: interoceptive dimensions in neurodegeneration and stroke.
Philos Trans R Soc Lond B Bio Sci 2016;371:20160006.
45. Melloni M, Sedeno L, Hesse E, et al. Cortical dynamics and subcortical signatures of
motor-language coupling in Parkinson’s disease. Sci Rep 2015;5:11899.
46. Ibanez A, Manes F. Contextual social cognition and the behavioral variant of frontotemporal dementia. Neurology 2012;78:1354–1362.
47. Pietto M, Parra MA, Trujillo N, et al. Behavioral and electrophysiological correlates of
memory binding deficits in patients at different risk levels for Alzheimer’s disease.
J Alzheimers Dis 2016;53:1325–1340.
48. Parra MA, Saarimaki H, Bastin ME, et al. Memory binding and white matter integrity
in familial Alzheimer’s disease. Brain 2015;138:1355–1369.
49. Parra MA, Abrahams S, Logie RH, Mendez LG, Lopera F, Della Sala S. Visual short-term
memory binding deficits in familial Alzheimer’s disease. Brain 2010;133:2702–2713.
50. Garcia-Cordero I, Sedeno L, Fraiman D, et al. Stroke and neurodegeneration induce
different connectivity aberrations in the insula. Stroke 2015;46:2673–2677.
51. Baez S, Pino M, Berrio M, et al. Corticostriatal signatures of schadenfreude: evidence
from Huntington’s disease. J Neurol Neurosurg Psychiatry 2018;89:112–116.
52. Lawlor DA, Tilling K, Davey Smith G. Triangulation in aetiological epidemiology. Int
J Epidemiol 2016;45:1866–1886.
53. Ardiles AO, Tapia-Rojas CC, Mandal M, et al. Postsynaptic dysfunction is associated
with spatial and object recognition memory loss in a natural model of Alzheimer’s
disease. Proc Natl Acad Sci USA 2012;109:13835–13840.
54. Parra M. Overcoming barriers in cognitive assessment of Alzheimer’s disease. Dement
Neuropsychol 2014;8:95–98.
55. Ibanez A, Parra MA. Mapping memory binding ontothe connectome’stemporal dynamics:
toward a combined biomarker for Alzheimer’s disease. Front Hum Neurosci 2014;8:237.
56. Scally B, Calderon P, Anghinah R, Parra M. Event-related potentials in the continuum
of Alzheimer’s disease: would they suit recent guidelines for preclinical assessment?
J Clin Diagn Res 2016;4. | |
